Table 2.
EV protein levels and WMLs
| Model | WML |
||
|---|---|---|---|
| WML at baseline n=994 | WML at follow-up* n=534 | ||
| EV-cystatin C (pg/µg) | I | 0.27 (0.20–0.34) | 0.06 (−0.02–0.13) |
| Mean 10.6 | II | 0.10 (0.04–0.17) | 0.01 (−0.06–0.08) |
| SD 5.3 | III | 0.10 (0.04–0.17) | 0.01 (−0.06–0.08) |
| EV-serpin G1 (pg/µg) | I | −0.03 (−0.10–0.05) | 0.02 (−0.05–0.08) |
| Mean 142.2 | II | −0.02 (−0.08–0.04) | 0.02 (−0.04–0.08) |
| SD 85.6 | III | −0.03 (−0.08–0.05) | 0.03 (−0.03–0.09) |
| EV-serpin F2 (pg/µg) | I | 0.01 (−0.066–0.08) | −0.01 (−0.08–0.05) |
| Mean 43.3 | II | 0.03 (−0.034–0.09) | 0.01 (−0.06–0.07) |
| SD 30.4 | III | 0.03 (−0.035–0.09) | 0.01 (−0.05–0.07) |
| EV-CD 14 (pg/µg) | I | 0.23 (0.16–0.30) | 0.12 (0.04–0.18) |
| Mean 12.2 | II | 0.14 (0.08–0.20) | 0.10 (0.03–0.17) |
| SD 3.9 | III | 0.14 (0.07–0.20) | 0.11 (0.04–0.18) |
Bold typeface indicates statistically significant results.
Regression coefficients: increase in WML (log%) per 1SD increase in EV protein level (pg/mL).
Model I: univariable model.
Model II: adjustment for age and gender.
Model III: Model II with additional adjustment for systolic blood pressure, pack years smoking and prevalent type 2 diabetes mellitus.
*Models include additional adjustment for baseline WML and follow-up time.
EV, extracellular vesicle; WMLs, white matter lesions